X

BIIB

Biogen Inc (BIIB) Biogen to Report Second Quarter 2022 Financial Results July 20, 2022

Biogen Inc (NASDAQ: BIIB) Q2 2022 Earnings Conference

Biogen Inc. (BIIB) Q2 2022 Earnings Call Transcript

Biogen Inc.  (NASDAQ: BIIB) Q2 2022 earnings call dated Jul. 20, 2022 Corporate Participants: Michael Hencke — Head of Investor Relations. Michel…

Infographic: Key highlights from Biogen (BIIB) Q2 2022 earnings results

Biogen Inc. (NASDAQ: BIIB) reported second quarter 2022 earnings results today. Total revenue decreased 7% year-over-year to $2.58 billion. Net…

Biogen’s (BIIB) long-term prospects look intact despite Alzheimer’s drug setback

Biogen Inc. (NASDAQ: BIIB) is currently going through a difficult phase as the biotechnology firm’s main products face stiff competition…

Key highlights from Biogen’s (BIIB) Q1 2022 earnings results

Biogen Inc. (NASDAQ: BIIB) reported first quarter 2022 earnings results today. Total revenue decreased 6% year-over-year to $2.53 billion. GAAP net…

Biogen Inc (BIIB) Biogen Fourth Quarter and Full Year 2021 Earnings Call

Biogen Inc (NASDAQ: BIIB) Q4 2021 Earnings Conference

Biogen, Inc. (BIIB) Q4 2021 Earnings Call Transcript

Biogen, Inc. (NASDAQ: BIIB) Q4 2021 earnings call dated Feb. 03, 2022 Corporate Participants: Michael Hencke — Head of Investor Relations Michel…

Biogen (BIIB) stock research summary | Q3 2021

Neurological and neurodegenerative diseases affect a vast segment of the population worldwide and there is a significant demand for treatments…

Biogen Inc (BIIB) Q3 2021 Earnings Call

Biogen Inc (NASDAQ: BIIB) Q3 2021 Earnings Conference

Biogen, Inc. (BIIB) Q3 2021 Earnings Call Transcript

Biogen, Inc.  (NASDAQ: BIIB) Q3 2021 earnings call dated Oct. 20, 2021 Corporate Participants: Michael Hencke — Investor Relations Michel Vounatsos — Chief Executive…